Hence, atezolizumab and pembrolizumab are now indicated for cisplatin-ineligible patients with advanced bladder cancer who have low PD-L1 expression or are ineligible for any platinum-containing chemotherapy [89,90]. The gene discussed is CD274; the disease is urinary bladder carcinoma.